Health Highlights: Jan. 6, 2010
FDA Cancels Cymbalta Meeting No Proof Virus Causes Chronic Fatigue Syndrome: Study Full-Body Airport Scanners No Health Threat: Experts No Big Change in FDA Drug Approvals Last Year
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
FDA Cancels Cymbalta Meeting
A meeting to consider an application to use the antidepressant Cymbalta to treat chronic pain has been canceled by the U.S. Food and Drug Administration because it wants time to review new information about the proposed use.
The meeting to review drug maker Eli Lilly & Co.'s application had been scheduled for Jan. 28, the Associated Press reported.
In November 2008, Lilly withdrew an application after FDA reviewers raised questions about the methodology and dosing in some of the company's clinical trials.
A new application submitted by Lilly last summer included data from studies on using Cymbalta to treat chronic pain caused by osteoarthritis and lower back pain, the AP reported.
Currently, the drug is approved in the United States for treatment of depression, generalized anxiety disorder, nerve pain and the pain condition fibromyalgia.
No Proof Virus Causes Chronic Fatigue Syndrome: Study
There's no evidence that a virus called XMRV causes chronic fatigue syndrome, says a British study that challenges recent research suggesting the virus could be responsible for the debilitating condition.
Imperial College London researchers analyzed blood samples from 186 patients with CFS and found that none of them had the virus, BBC News reported.
"We are confident that are results show there is no link between XMRV and chronic fatigue syndrome, at least in the U.K.," said investigator Professor Myra McClure.
Experts said the study findings, published in the journal PLoS One, will be bitterly disappointing to many patients who'd pinned their hopes on drugs to fight XMRV, BBC News reported.
Full-Body Airport Scanners No Health Threat: Experts
While some are concerned about cumulative radiation exposure from full-body scanners used for airport security, most experts say such fears are unfounded, according to ABC News.
Use of the scanners is expected to increase in the wake of the alleged failed bombing attempt on an Amsterdam-to-Detroit flight on Christmas Day.
The full-body scanners use a technology called backscatter X-rays, which deliver a low dose of radiation, explained Dr. James Thrall, chairman of the American College of Radiology and chairman of radiology at Massachusetts General Hospital in Boston.
"Moreover, the individual X-rays themselves are very low energy, and unlike the X-ray spectrum that we use in medicine, the backscatter X-rays don't really penetrate to the organs in the body," he told ABC News.
Thrall said a person would have to "take hundreds and hundreds of trips requiring screening to even reach what would be considered a negligible dose" of radiation.
No Big Change in FDA Drug Approvals Last Year
The number of drugs approved last year by the U.S. Food and Drug Administration was about the same as in 2008, and the number of warnings issued by the agency decreased, according to figures released by the investment research group Washington Analysis.
In 2009, the FDA approved 26 first-of-a-kind prescription drugs, compared with 25 in 2008. An FDA spokeswoman wouldn't confirm or comment on the number of drugs approved last year, the Associated Press reported.
Washington Analysis also said the FDA last year added 31 new or updated "black box" warnings to drugs already on the market, compared with 56 boxed warnings in 2008.
The drug industry had been worried that the Obama administration would take a much tougher stance on drug safety than the Bush administration, but these figures suggest a moderate approach, the AP reported.